Evidence map›Paper›PMID 40507914›Full record

ArticleInternational journal of molecular sciences2025

Integrative Single-Cell and Bulk RNA Sequencing Identifies a Glycolysis-Related Prognostic Signature for Predicting Prognosis in Pancreatic Cancer.

Nan Wu, Chong Zhou, Xu Yan, Ziang Liu, Ruohan Jiang, Yuzhou Luo, Ping Jiang, Yu Mu, Shan Xiao, Xien Huang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nan WuLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.ORCID 0000-0002-7401-4136
Chong ZhouLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Xu YanLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Ziang LiuLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Ruohan JiangLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Yuzhou LuoLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Ping JiangLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Yu MuLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Shan XiaoLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Xien HuangLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Yunzhen ZhouLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Donglin SunLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.
Yan JinLaboratory of Medical Genetics, Harbin Medical University, #157 Bao Jian Road, Harbin 150081, China.ORCID 0000-0001-6282-7095

Funding

Heilongjiang Touyan Innovation Team Program, Scientific research funds of Heilongjiang pro-vincial scientific research institutes CZKYF2021-2-B012National Natural Science Foundation of China 82172353Natural Science Foundation of Heilongjiang Province YQ2022H004Natural Science Foundation of Heilongjiang Province ZD2023H002
6 · The paper itself

Abstract

Alterations in glycolysis play a crucial role in cancer cells, influencing tumor aggressiveness and therapeutic effect, particularly in pancreatic adenocarcinoma (PAAD). However, the specific glycolysis-related genes involved in PAAD progression remain poorly understood. This study established glycolysis-related molecular subtypes with distinct survival outcomes using TCGA datasets. The favorable prognosis subtype exhibited enhanced immune infiltration and an activated tumor microenvironment. A glycolysis prognostic model effectively predicted PAAD survival, correlating with global glycolytic pathways, and AUCell evaluated neutrophil communication networks of models. Functional validation demonstrated that ENO1/PGM2L1 co-expression promoted tumor proliferation, migration, invasion, and glycolytic flux in vitro, while accelerating xenograft growth in vivo. Conversely, their knockdown suppressed malignancy. Our study demonstrated that the glycolytic prognostic risk model serves as a reliable tool for prognosis and prediction of PAAD progression. ENO1 and PGM2L1 emerge as key risk factors promoting the malignant progression of PAAD.

Indexed as

GlycolysisPancreatic NeoplasmsSingle-Cell AnalysisAnimalsBiomarkers, TumorCell Line, TumorCell ProliferationDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHumansMaleMicePhosphopyruvate HydratasePrognosisSequence Analysis, RNABiomarkers, TumorDNA-Binding ProteinsENO1 protein, humanPhosphopyruvate HydrataseTumor Suppressor ProteinsENO1glycolysispancreatic adenocarcinomapancreatic cancerPGM2L1risk model

Identifiers

PMID40507914
PMCPMC12154285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.